Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:70004 |
Name | myeloid neoplasm |
Definition | A bone marrow cancer that is formed of any one of the bone marrow cells belonging to the granulocytic (neutrophil, eosinophil, basophil), monocytic/macrophage, erythroid, megakaryocytic and mast cell lineages. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FGFR3 K650E FGFR3 over exp HRAS K117E | AZ8010 | myeloid neoplasm | sensitive | detail... |
FGFR3 wild-type | SSR128129E | myeloid neoplasm | sensitive | detail... |
FGFR3 K650E | SSR128129E | myeloid neoplasm | no benefit | detail... |
FGFR3 Y373C | Zoligratinib | myeloid neoplasm | sensitive | detail... |
FGFR3 K650E | Zoligratinib | myeloid neoplasm | sensitive | detail... |
FGFR3 F386L | Zoligratinib | myeloid neoplasm | sensitive | detail... |
FGFR3 wild-type | SU5402 | myeloid neoplasm | sensitive | detail... |
FGFR3 K650E | SU5402 | myeloid neoplasm | sensitive | detail... |
FGFR3 rearrange | PRN1371 | myeloid neoplasm | sensitive | detail... |
FGFR3 Y373C | RO4987655 | myeloid neoplasm | no benefit | detail... |
FGFR3 Y373C | RO5126766 | myeloid neoplasm | no benefit | detail... |
FGFR3 Y373C | Selumetinib | myeloid neoplasm | no benefit | detail... |
FGFR3 rearrange | Fexagratinib | myeloid neoplasm | sensitive | detail... |
IDH1 mutant | Ivosidenib + Venetoclax | myeloid neoplasm | predicted - sensitive | detail... |
IDH1 mutant | Azacitidine + Ivosidenib + Venetoclax | myeloid neoplasm | predicted - sensitive | detail... |
JAK2 rearrange | Ruxolitinib | myeloid neoplasm | sensitive | detail... |
JAK2 rearrange | Fedratinib | myeloid neoplasm | sensitive | detail... |
ABL1 rearrange | Dasatinib | myeloid neoplasm | sensitive | detail... |
ABL1 rearrange | Nilotinib | myeloid neoplasm | sensitive | detail... |
ABL1 rearrange | Imatinib | myeloid neoplasm | sensitive | detail... |
ABL1 rearrange | Bosutinib | myeloid neoplasm | sensitive | detail... |
ABL1 rearrange | Ponatinib | myeloid neoplasm | sensitive | detail... |
FLT3 rearrange | Gilteritinib | myeloid neoplasm | sensitive | detail... |
FLT3 rearrange | Midostaurin | myeloid neoplasm | sensitive | detail... |
FLT3 rearrange | Sorafenib | myeloid neoplasm | sensitive | detail... |
FLT3 rearrange | Sunitinib | myeloid neoplasm | sensitive | detail... |
ABL1 rearrange | Asciminib | myeloid neoplasm | sensitive | detail... |
FLT3 rearrange | Quizartinib | myeloid neoplasm | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01885897 | Phase Ib/II | Nogapendekin alfa inbakicept | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | Completed | USA | 0 |
NCT02420860 | Phase II | Famotidine Elotuzumab + Lenalidomide Diphenhydramine Dexamethasone | Study of Elotuzumab With Lenalidomide as Maintenance After Autologous Stem Cell Transplant (ASCT) | Active, not recruiting | USA | 0 |
NCT02506959 | Phase II | Dexamethasone Busulfan + Melphalan Pyridoxine Panobinostat Palifermin Gemcitabine | Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma | Completed | USA | 0 |
NCT02843074 | Phase II | Dexamethasone + Elotuzumab + Lenalidomide | Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients | Completed | USA | 0 |
NCT02969837 | Phase II | Carfilzomib + Dexamethasone + Elotuzumab + Lenalidomide | Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT03503968 | Phase Ib/II | MDG1011 | TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms | Terminated | DEU | 0 |
NCT03531918 | Phase Ib/II | Cladribine + Cytarabine + Filgrastim + Gemtuzumab ozogamicin + Mitoxantrone Cladribine + Cytarabine + Filgrastim | Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine and Mitoxantrone in Treating Participants With Previously Untreated Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm | Completed | USA | 0 |
NCT03862157 | Phase Ib/II | Azacitidine + MLN4924 + Venetoclax | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT04189445 | Phase II | Futibatinib | Futibatinib in Patients With Specific FGFR Aberrations | Completed | USA | TUR | SWE | NLD | ITA | GBR | FRA | ESP | DEU | BEL | 5 |
NCT04195945 | Phase II | CPX-351 Cladribine + Cytarabine + Filgrastim + Mitoxantrone | CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients | Active, not recruiting | USA | 0 |
NCT04797767 | Phase I | Cladribine + Cytarabine + Mitoxantrone + Sargramostim + Venetoclax | Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms | Recruiting | USA | 0 |